If the CanniMed proxy is successful at getting the shareholders to reject the ACB deal, then for several reasons, there’s going to be some disappointment shared by many. jmo
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.